Skip to main content

Pete Lucas

Analyst

CJS Securities

Equibles does not estimate personal net worth.

About Pete Lucas

Pete Lucas is recorded as Analyst at CJS Securities. Pete Lucas has spoken on 9 earnings calls across 8 companies, most recently for Lci Industries on November 5, 2026. Those appearances were for Lci Industries (LCII), Spectrum Brands Holdings, Inc. (SPB), Icu Medical Inc (ICUI), Haemonetics Corp (HAE), Energy Recovery, Inc. (ERII) and 3 other companies. The companies whose calls Pete Lucas spoke on are classified in the Consumer Cyclical, Healthcare, Consumer Defensive and Industrials sectors.

Pete Lucas on recent calls

“Just looking at your revised outlook of approximately flat for RV demand and shipments next year, what gives you the confidence that this year is the bottom, and how are you thinking about potential for upside or downside to those projections?”
Analyst — CJS Securities, Q3 FY2026 Earnings conference call (announced in 8-K) ·
“Just, I guess, a bigger picture question in terms of retail demand. Obviously, lots of headwinds, interest rates, inflation, oil prices. But just kind of wanted to get your thoughts.”
Analyst — CJS Securities, Q2 2026 LCI Industries Earnings Conference Call ·
“You guys covered a lot in the prepared remarks. Maybe more just a general question. If you could talk a little bit about the characteristics of your fastest growing brands in PET and H&G, and is there an opportunity to replicate that across the rest of the brand portfolio?”
Analyst — CJS Securities, Spectrum Brands Holdings, Inc. Q2 FY2026 Earnings Call ·
“In your prepared remarks, you mentioned gross margin of 41% ahead of estimates due to favorable mix. Do you see this as sustainable, and can you kind of give us an idea of cadence through the year and the overall OPEX on this and the overall OPEX, I should say?”
Analyst — CJS Securities, Icu Medical Inc/De Q1 FY2026 Earnings Call ·
“Just following up on Percocille, should we expect incremental sales and marketing investment in fiscal year 27 ahead of when approved, and how should we kind of think about that?”
Analyst — CJS Securities, Haemonetics Corp Q4 FY2026 Earnings Call ·

Affiliation history

  • CJS Securities

    Analyst

    Source not stated

    Current

Company network

Recent activity